Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: A pooled analysis of three prospective phase I-II trials

International Journal of Radiation Oncology Biology Physics

Volumn 78, Issue 2, 2010, Pages 472-478

  Weiss, Christian ^a   Arnold, Dirk ^b   Dellas, Kathrin ^b   Liersch, Torsten ^c   Hipp, Matthias ^d   Fietkau, Rainer ^e   Sauer, Rolf ^e   Hinke, Axel ^f   Rödel, Claus ^a  

^a GOETHE UNIVERSITY   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d UNIVERSITY OF REGENSBURG   (Germany)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^f Research Institute Pharma GmbH   (Germany)

Author keywords

Capecitabine; Cetuximab; Oxaliplatin; Radiochemotherapy; Rectal cancer

Indexed keywords

CAPECITABINE; CETUXIMAB; OXALIPLATIN; RADIOCHEMOTHERAPY; RECTAL CANCER;

DISEASES; FAULT TOLERANT COMPUTER SYSTEMS; NATURAL LANGUAGE PROCESSING SYSTEMS; SURGERY; TOXICITY; TUMORS;

MULTIVARIANT ANALYSIS;

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CAPECITABINE; CETUXIMAB; CREATININE; OXALIPLATIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; FLUOROURACIL; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ACNE; ACUTE TOXICITY; ADULT; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANEMIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER REGRESSION; CANCER STAGING; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DISEASE SEVERITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DYSPNEA; FEMALE; HAND FOOT SYNDROME; HUMAN; ILEUS; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MULTIVARIATE ANALYSIS; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROCTITIS; PROSPECTIVE STUDY; PROTEINURIA; RADIATION DERMATITIS; RECTUM CANCER; RECTUM FISTULA; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNIVARIATE ANALYSIS; URINE RETENTION; ADJUVANT THERAPY; AGE; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; META ANALYSIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROCEDURES; RECTAL NEOPLASMS; REMISSION; SEX DIFFERENCE;

AGE FACTORS; ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES; RECTAL NEOPLASMS; REMISSION INDUCTION; SEX FACTORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC;

EID: 84755160772     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.07.1718     Document Type: Article

References (32)

1. J.F. Bosset, L. Collette, and G. Calais Chemotherapy with preoperative radiotherapy in rectal cancer N Engl J Med 355 2006 1114 1123
2. J.P. Gerard, T. Conroy, and F. Bonnetain Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: Results of FFCD 9203 J Clin Oncol 24 2006 4620 4625
3. R. Sauer, H. Becker, and W. Hohenberger Preoperative versus postoperative chemoradiotherapy for rectal cancer N Engl J Med 351 2004 1731 1740
4. C. Rodel, and R. Sauer Integration of novel agents into combined-modality treatment for rectal cancer patients Strahlenther Onkol 183 2007 227 235
5. C. Aschele, C. Pinto, and S. Cordio Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: Pathologic response analysis of the Studio Terapia Adiuvante Retto (STAR)-01 randomized phase III trial J Clin Oncol 27 2009 CRA4008
6. J. Gerard, D. Azria, and S. Gourgou-Bourgade Randomized multicenter phase III trial comparing two neoadjuvant chemoradiotherapy (CT-RT) regimens (RT45-Cap versus RT50-Capox) in patients (pts) with locally advanced rectal cancer (LARC): Results of the ACCORD 12/0405 PRODIGE 2 J Clin Oncol 27 2009 LBA4007
7. F. Marquardt, F. Rodel, and G. Capalbo Molecular targeted treatment and radiation therapy for rectal cancer Strahlenther Onkol 185 2009 371 378
8. D. Azria, F. Bibeau, and N. Barbier Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer BMC Cancer 5 2005 62
9. F. Bertolini, C. Bengala, and L. Losi Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy Int J Radiat Oncol Biol Phys 68 2007 1455 1461
10. J. Giralt, M. de las Heras, and L. Cerezo The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: A multicenter, retrospective analysis Radiother Oncol 74 2005 101 108
11. J.S. Kim, J.M. Kim, and S. Li Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy Int J Radiat Oncol Biol Phys 66 2006 195 200 (Pubitemid 44175651)
12. S. Li, J.S. Kim, and J.M. Kim Epidermal growth factor receptor as a prognostic factor in locally advanced rectal-cancer patients treated with preoperative chemoradiation Int J Radiat Oncol Biol Phys 65 2006 705 712 (Pubitemid 43795832)
13. K.L. Spindler, J.N. Nielsen, and J. Lindebjerg Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region Int J Radiat Oncol Biol Phys 66 2006 500 504
14. I. Zlobec, T. Vuong, and C.C. Compton Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy Br J Cancer 98 2008 450 456
15. C. Schutze, A. Dorfler, and W. Eicheler Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma Strahlenther Onkol 183 2007 256 264
16. J.A. Bonner, P.M. Harari, and J. Giralt Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 2006 567 578
17. K. Horisberger, A. Treschl, and S. Mai Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: Results of a Phase II MARGIT Trial Int J Radiat Oncol Biol Phys 74 2009 1487 1493
18. F. Bertolini, S. Chiara, and C. Bengala Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: A phase II study in locally advanced rectal cancer Int J Radiat Oncol Biol Phys 73 2009 466 472
19. E.C. Cabebe, T. Kuo, and A. Koong Phase I trial of preoperative cetuximab in combination with oxaliplatin, capecitabine, and radiation therapy for locally advanced rectal cancer (abstr. 15019) J Clin Oncol 26 2008
20. K.Y. Chung, B. Minsky, and D. Schrag Phase I trial of preoperative cetuximab with concurrent continuous infusion 5-fluorouracil and pelvic radiation in patients with local-regionally advanced rectal cancer (abstract) J Clin Oncol 24 2006 3560
21. J.P. Machiels, C. Sempoux, and P. Scalliet Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer Ann Oncol 18 2007 738 744
22. C. Rodel, D. Arnold, and M. Hipp Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer Int J Radiat Oncol Biol Phys 70 2008 1081 1086
23. C. Rödel, G.G. Grabenbauer, and T. Papadopoulos Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer J Clin Oncol 21 2003 3098 3104
24. C. Rodel, T. Liersch, and R.M. Hermann Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer J Clin Oncol 25 2007 110 117
25. O. Dworak, L. Keilholz, and A. Hoffmann Pathological features of rectal cancer after preoperative radiochemotherapy Int J Colorectal Dis 12 1997 19 23
26. M.P. Morelli, T. Cascone, and T. Troiani Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors Ann Oncol 16 Suppl 4 2005 iv61-iv68
27. D. Raben, B. Helfrich, and D.C. Chan The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer Clin Cancer Res 11 2005 795 805
28. M.K. Nyati, M.A. Morgan, and F.Y. Feng Integration of EGFR inhibitors with radiochemotherapy Nat Rev Cancer 6 2006 876 885
29. W. De Roock, H. Piessevaux, and J. De Schutter KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab Ann Oncol 19 2008 508 515
30. A. Daemen, O. Gevaert, and T. De Bie Integrating microarray and proteomics data to predict the response on cetuximab in patients with rectal cancer Pac Symp Biocomput 2008 166 177
31. A. Debucquoy, K. Haustermans, and A. Daemen Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer J Clin Oncol 27 2009 2751 2757
32. C. Bengala, S. Bettelli, and F. Bertolini Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer Ann Oncol 20 2009 469 474